Chimeric Therapeutics Ltd continues to develop oncology pipeline providing benefits to cancer patients globally
Chimeric Therapeutics Ltd (ASX:CHM) continues to develop its oncology pipeline with novel cell therapy technologies to provide benefits to cancer patients globally. In its March quarter report, the company highlighted its healthy financial position, with $23.6 million in cash and equivalents as of March 31. Successful initial public offering During the quarter, Chimeric completed a $35 million initial public offering (IPO) and successfully listed on the ASX in January with support from new and existing institutional, professional and retail investors within Australia and overseas. Proceeds ...
Source: proactiveinvestors.com.au